Unmatched Precision.‡
Unequivocal Excellence.

Robotic accuracy for prostate disease management →

BIOBOT Successfully Closes S$24 MM Series B Funding Round

A white arrow pointing to the top right.

Addressing
a Critical Unmet Need

In the realm of prostate cancer care, a substantial gap persists. Prostate cancer stands as the second-leading cause of cancer-related deaths in men, with over 1.2M men diagnosed annually, and 1 in 8 facing a diagnosis in their lifetime. 1

While early diagnosis and timely intervention are pivotal for saving lives and maintaining quality of life, the existing standard of care falls short in meeting the pressing needs of men. We strive to bridge this gap, offering transformative solutions in prostate cancer care. →

A black-and-white photo of a doctor reassuring a patient. Decorative blue box and thin black lines in the background.

The Biobot Difference

First in class, only in class

+
Pioneers in the field of robotic transperineal prostate procedures

+
Dedicated to advancing prostate care through technology

Meaningful impact

+
Improving diagnostics for the most common cancer among men 2

+
50+ units installed globally

Significant traction

+
5 key regulatory clearances 3

+
Over 23,000 procedures completed with urologists 4

+
Strong development pipeline into new indications and expanded sites of care

+
IP-protected

The precision
urologists require
and patients
deserve →

Profile photo of Mona Lisa 2.0 [TX] robot with pale blue grid behind it.
An icon with "+/- 1.0" text.

Unmatched robotic accuracy

Robotic-assisted needle positioning provides accuracy within 1.0  mm

An icon of badge with letters TP inside.

Supporting the new standard of care

Enabling urologists to deliver prostate biopsies percutaneously — with minimal infection rates and maximal prostate coverage

An icon of a 3D prostate in a cube.

Advanced visualization for better outcomes

Unique fusion of MRI and ultrasound imaging leads to higher detection rates as compared to transrectal biopsies

Innovation Pipeline

We are investing in continuous development of the system’s digital infrastructure as well as expanding into new indications and sites of care.

White outlined text "Mona Lisa", black text "[DX]" below it.
White outlined text "Mona Lisa", black text "2.0 [TX]" below it.
White outlined text "Mona Lisa", orange text "ACCuESS" below it.
White outlined text "Mona Lisa", black text "[DX]" below it.

First model, launched in 2017 for targeted prostate biopsies.

This video is intended for clinical professionals and not for general public.

White outlined text "Mona Lisa", black text "2.0 [TX]" below it.

Expanded indications to include soft tissue ablation treatment.

White outlined text "Mona Lisa", orange text "ACCuESS" below it.

Coming in 2025: expanding sites of care and indications.

‡ Based on internal bench testing.

  1. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html
  2. https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/cancer-facts/cancer-facts-for-men.html
  3. Mona Lisa [Dx]: has FDA, NMPA, TGA and HSA clearances.Mona Lisa 2.0 [Tx]: has FDA, TGA and HSA clearances, with CE and NMPA expected in 2024 and 2025, respectively.
  4. Based on internal estimate on 31 January 2024.